Welcome to NeurologyLive® Brain Games! This weekly quiz series, which goes live every Sunday morning, will feature questions ...
PROPEL will test imeroprubart, an investigational FcRn blocker, against placebo in adults with mild to severe generalized ...
Congressional passage would extend ACT for ALS programs and associated research grants through FY2031, sustaining federal ...
Cluster headache care remains hindered by migraine overlap, contributing to diagnostic delay and prolonged unmet need for ...
Treatment initiation before 90 days correlated with markedly higher independent walking (73.2% vs 36.7%) and fewer ...
The professor of neurology at the University of Lyon and 2026 Rachel Horne Prize Winner discussed pregnancy counseling, ...
The investigators set out to indirectly compare nipocalimab's safety, specifically any adverse event (AE) and any serious ...
Tasimelteon advanced sleep onset by 42.5 minutes versus 5.4 minutes with placebo in DSWPD, meeting the primary endpoint with ...
A prospective, multicenter real-world study, dubbed ADHERE REAL (NCT07264426), will evaluate the effectiveness of ...
The FDA has approved tavapadon (AbbVie), a once-daily oral selective dopamine D1/D5 receptor partial agonist, for adults with ...
The FDA extended its review of relutrigine for SCN2A- and SCN8A-related epilepsies by three months, pushing the PDUFA date to ...
FcRn blockade with nipocalimab necessitates pregnancy surveillance because placental FcRn drives maternal–fetal IgG transfer, ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results